$EVO

Evotec SE (EVO) reported Q2 2026 revenue of €143.5m, down from €171.2m, and adjusted EBITDA of -€20.8m. H1 revenue fell to €300.1m from €371.2m, with adjusted EBITDA -€42.7m. It reaffirmed FY2026 guidance: revenue €570-€610m and adjusted EBITDA -€70 to -€105m, citing partnership phasing and slower new ramp-ups.

Evotec (NASDAQ: EVO) reaffirmed its FY2026 sales guidance of $667.470 million to $714.310 million, unchanged from prior outlook and near the consensus estimate of $673.750 million. The company also announced an R&D collaboration with Odyssey Therapeutics (NASDAQ: ODTX) to discover small-molecule candidates for autoimmune and inflammatory diseases, with milestone payments and no disclosed upfront terms.

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

Evotec SE (NASDAQ: EVO) said it entered an R&D collaboration with Odyssey Therapeutics (NASDAQ: ODTX) to use Evotec’s AI-enabled discovery platform and screening capabilities to discover and validate small-molecule drug candidates for autoimmune and inflammatory diseases. Evotec will deliver validated hit series across multiple targets and may receive milestone payments; no financial terms were disclosed.

Evolution AB (publ) said it bought 207,007 of its own shares on 3 Aug 2026, pushing its treasury shareholding above the 5% notification threshold. The company now holds 9,985,643 own shares, or 5.01% of 199,226,613 shares and votes. The buyback is part of a program for up to 19,922,661 shares and EUR 2 billion announced 18 May 2026.

Navan (NASDAQ: NAVN) said Evotec (NASDAQ: EVO; Frankfurt: EVT) selected Navan to run its global travel and expense program across Germany, the UK, U.S., Italy, and France. Evotec aims to unify tools, reduce manual expense entry, and automate reconciliation from card swipes, according to the companies.

Evotec said unfavorable FX will cut first-half revenue by about €13 million. It guided Q2 adjusted group EBITDA to about -€20.8 million and -€42.7 million for 1H 2026. Full-year 2026 revenue is now ~€570m-€610m (inc. FX) and adjusted EBITDA -€70m to -€105m. Liquidity rose to €465.6m.

Evotec SE (NASDAQ: EVO) reported preliminary, unaudited Q2 and first-half 2026 results and updated its full-year outlook. It expects H1 2026 revenue of about €300.1m and adjusted EBITDA of about -€42.7m, with liquidity around €465.6m as of June 30. Full-year 2026 revenue guidance is €570-610m and adjusted EBITDA -€70 to -105m, down from prior €700-780m and €0-40m.

Evotec SE (EVO) launched J.TRAIN, a turnkey continuous biopharmaceutical manufacturing solution for partners to install on-site. It combines modular cleanrooms, cGMP-compliant automation, and digital validation, aiming for capacity setup in as little as 18 months. Evotec cited a December 2025 Sandoz deal and said J.TRAIN was unveiled in April 2026. EVO stock last close: $2.80 (+2.19%).

Evotec SE, a German drug discovery specialist, continues to attract attention for its refining pipeline and global footprint, particularly among biotech-focused investors. The company operates as a global research and development platform for pharmaceutical and biotech groups, leveraging a diversified partnering model that includes fee-for-service contracts, integrated alliances, and potential milestone and royalty income. This approach aims to spread scientific and financial risk while providing exposure to the biotechnology innovation landscape for US and international investors.